Avextra

About Avextra

Based in Bensheim, Germany, Avextra AG operates as a vertically integrated biopharmaceutical company specializing in cannabis-based medicines. Founded in 2019, the company oversees its entire value chain, from cultivating proprietary cannabis genetics in Portugal to EU-GMP certified manufacturing at its state-of-the-art facility in Germany. This comprehensive control enables the development of precisely formulated, regulator-approved medical products. The company was established by founders including Dr. Bernhard Babel and David Reckeweg-Lecompte. Dr. Babel brought over 15 years of experience in regulatory affairs and business development, including roles at McKinsey, while Reckeweg-Lecompte contributed extensive experience in herbal medicine and global business development from his leadership at Dr. Reckeweg & Co.

Avextra's business model is centered on a research-driven, two-pillar strategy: delivering unregistered cannabis-based medicines to meet immediate patient needs and investing heavily in clinical trials to develop proprietary, registered prescription drugs. The company collaborates with physicians, researchers, and scientific associations through its "Alliance for Evidence-Based Cannabis-Medicine" to gather real-world data and conduct robust clinical studies. Revenue is generated through the distribution and sale of its cannabis-based products across a network in key European markets, including Germany, Italy, Switzerland, and the UK.

The company's product portfolio includes a range of cannabis extracts and oral formulations, such as the balanced 10 THC/10 CBD extract and a 25/25 extract, designed to treat symptoms for which conventional therapies have proven insufficient. A significant focus is placed on palliative care, neuropathic pain, and neurodegenerative diseases. Avextra is actively conducting several clinical trials, including the Phase 2 BELCANTO trial in Germany for cancer patients in palliative care and the Phase 2 NEUROBIS trial in Italy for patients with ALS, Alzheimer's, and Parkinson's disease. Retrospective studies like OCEAN-R have shown promising results for its Avextra 10/10 product in treating chemotherapy-induced neuropathic pain, demonstrating significant symptom relief and improved quality of life. Through strategic partnerships, such as with SynQube GmbH and IUCS-CESPU in Portugal, Avextra is also exploring the development of other psychotropic substances, like psilocybin, and investing in R&D for new medical devices and extraction methods.